Skip to main content
Top
Published in: Pituitary 4/2014

01-08-2014

Increased thyroid cancer risk in acromegaly

Authors: Selcuk Dagdelen, Nese Cinar, Tomris Erbas

Published in: Pituitary | Issue 4/2014

Login to get access

Abstract

Acromegaly increases cancer risk. We aimed to determine the prevalence and the predictors of tumors in acromegalic patients treated at our department. We retrospectively evaluated 160 acromegalic patients [79 female (mean age 52.0 ± 10.4 years) and 81 male (mean age 49.1 ± 12.4 years)] between 1990 and 2012, with a mean follow up period of 7.1 ± 5.7 years. The patients were screened with colonoscopy, mammography, thyroid and prostate ultrasonography. Malignancy was found in 34 (21.3 %) patients. No significant difference was observed in the distribution of malignancy among sexes (20.3 % in F vs. 22.2 % in M). Thyroid cancer was the most frequent (n = 17, 10.6 %) followed by the breast cancer (n = 4, 2.5 %) and colorectal cancer (n = 3, 1.8 %). Renal cell cancer in two patients, bladder cancer in two patients, periampullary tumor, rectal carcinoid tumor, malignant melanoma, prostate cancer, lung cancer, parotid mucoepidermoid carcinoma and malignant mesenchymal tumor in brain in one patient were detected. One patient had both thyroid and renal cell cancer. Age of patients at diagnosis of acromegaly was significantly higher in patients with cancer (45.8 ± 9.9 vs. 40.9 ± 11.3 years, p < 0.05). No significant difference was found in duration of the disease, initial GH levels and IGF-1 % upper limit of normal values, the prevalence of diabetes, hypertension, coronary heart disease, hyperlipidemia and treatment modalities between the patients with/without cancer. In logistic regression analysis, older age at diagnosis was associated with malignancy risk. The risk of cancer in acromegaly especially the thyroid cancer risk seems to be more increased than known in the literature. Therefore, acromegaly patients should be screened routinely for cancer, especially for thyroid cancer due to it being up to four times higher prevalence than breast and colorectal cancer.
Literature
1.
go back to reference Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151(8):1629–1632PubMedCrossRef Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151(8):1629–1632PubMedCrossRef
2.
go back to reference Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J, The Pituitary Study Group (1998) Increased incidence of neoplasia in patients with pituitary adenomas. Clin Endocrinol (Oxf) 49(4):441–445CrossRef Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J, The Pituitary Study Group (1998) Increased incidence of neoplasia in patients with pituitary adenomas. Clin Endocrinol (Oxf) 49(4):441–445CrossRef
3.
go back to reference Jenkins PJ, Besser M (2001) Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 86(7):2935–2941PubMedCrossRef Jenkins PJ, Besser M (2001) Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 86(7):2935–2941PubMedCrossRef
4.
8.
go back to reference Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ (2000) Insulin like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 60(7):2007–2017PubMed Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ (2000) Insulin like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 60(7):2007–2017PubMed
10.
go back to reference Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83(8):2730–2734PubMed Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83(8):2730–2734PubMed
11.
go back to reference Bayram F, Gedik VT, Demir O, Kaya A, Gundogan K, Emral R, Ozturk A, Uysal AR, Corapcioglu D (2011) Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay. Endocrine 40(2):304–309. doi:10.1007/s12020-011-9476-z PubMedCrossRef Bayram F, Gedik VT, Demir O, Kaya A, Gundogan K, Emral R, Ozturk A, Uysal AR, Corapcioglu D (2011) Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay. Endocrine 40(2):304–309. doi:10.​1007/​s12020-011-9476-z PubMedCrossRef
12.
go back to reference Mustacchi P, Shimkin MB (1957) Occurrence of cancer in acromegaly and in hypopituitarism. Cancer 10(1):100–104PubMedCrossRef Mustacchi P, Shimkin MB (1957) Occurrence of cancer in acromegaly and in hypopituitarism. Cancer 10(1):100–104PubMedCrossRef
13.
go back to reference Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13(5):395–400PubMedCrossRef Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13(5):395–400PubMedCrossRef
14.
go back to reference Higuchi Y, Saeki N, Iuchi T, Uchino Y, Tatsuno I, Uchida D, Tanaka T, Noguchi Y, Nakamura S, Yasuda T, Yamaura A, Sunami K, Oka Y, Uozumi A (2000) Incidence of malignant tumors in patients with acromegaly. Endocr J 47(Suppl):S57–S60PubMedCrossRef Higuchi Y, Saeki N, Iuchi T, Uchino Y, Tatsuno I, Uchida D, Tanaka T, Noguchi Y, Nakamura S, Yasuda T, Yamaura A, Sunami K, Oka Y, Uozumi A (2000) Incidence of malignant tumors in patients with acromegaly. Endocr J 47(Suppl):S57–S60PubMedCrossRef
15.
go back to reference Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Uum S, Rivera J, Caspar-Bell G, Serri O (2012) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf). doi:10.1111/cen.12112 Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Uum S, Rivera J, Caspar-Bell G, Serri O (2012) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf). doi:10.​1111/​cen.​12112
16.
go back to reference Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81(3):1169–1172PubMed Bates AS, Van’t Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81(3):1169–1172PubMed
17.
go back to reference Eser S, Yakut C, Ozdemir R, Karakilinc H, Ozalan S, Marshall SF, Karaoglanoglu O, Anbarcioglu Z, Ucuncu N, Akin U, Ozen E, Ozgul N, Anton-Culver H, Tuncer M (2010) Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev 11(6):1731–1739PubMed Eser S, Yakut C, Ozdemir R, Karakilinc H, Ozalan S, Marshall SF, Karaoglanoglu O, Anbarcioglu Z, Ucuncu N, Akin U, Ozen E, Ozgul N, Anton-Culver H, Tuncer M (2010) Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev 11(6):1731–1739PubMed
19.
go back to reference Miyakawa M, Saji M, Tsushima T, Wakai K, Shizume K (1988) Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels. J Clin Endocrinol Metab 67(5):973–978PubMedCrossRef Miyakawa M, Saji M, Tsushima T, Wakai K, Shizume K (1988) Thyroid volume and serum thyroglobulin levels in patients with acromegaly: correlation with plasma insulin-like growth factor I levels. J Clin Endocrinol Metab 67(5):973–978PubMedCrossRef
20.
go back to reference Kasagi K, Shimatsu A, Miyamoto S, Misaki T, Sakahara H, Konishi J (1999) Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid 9(8):791–796PubMedCrossRef Kasagi K, Shimatsu A, Miyamoto S, Misaki T, Sakahara H, Konishi J (1999) Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid 9(8):791–796PubMedCrossRef
21.
go back to reference Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A (2002) Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25(3):240–245PubMedCrossRef Gasperi M, Martino E, Manetti L, Arosio M, Porretti S, Faglia G, Mariotti S, Colao AM, Lombardi G, Baldelli R, Camanni F, Liuzzi A (2002) Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest 25(3):240–245PubMedCrossRef
22.
go back to reference Cheung NW, Boyages SC (1997) The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 46(5):545–549CrossRef Cheung NW, Boyages SC (1997) The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 46(5):545–549CrossRef
24.
go back to reference Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T (2013) Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine. doi:10.1007/s12020-013-9981-3 Dogan S, Atmaca A, Dagdelen S, Erbas B, Erbas T (2013) Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. Endocrine. doi:10.​1007/​s12020-013-9981-3
25.
go back to reference Erdogan G, Erdogan MF, Emral R, Bastemir M, Sav H, Haznedaroglu D, Ustundag M, Kose R, Kamel N, Genc Y (2002) Iodine status and goiter prevalence in Turkey before mandatory iodization. J Endocrinol Invest 25(3):224–228PubMedCrossRef Erdogan G, Erdogan MF, Emral R, Bastemir M, Sav H, Haznedaroglu D, Ustundag M, Kose R, Kamel N, Genc Y (2002) Iodine status and goiter prevalence in Turkey before mandatory iodization. J Endocrinol Invest 25(3):224–228PubMedCrossRef
26.
go back to reference Erdogan MF, Agbaht K, Altunsu T, Ozbas S, Yucesan F, Tezel B, Sargin C, Ilbeg I, Artik N, Kose R, Erdogan G (2009) Current iodine status in Turkey. J Endocrinol Invest 32(7):617–622. doi:10.3275/6379 PubMedCrossRef Erdogan MF, Agbaht K, Altunsu T, Ozbas S, Yucesan F, Tezel B, Sargin C, Ilbeg I, Artik N, Kose R, Erdogan G (2009) Current iodine status in Turkey. J Endocrinol Invest 32(7):617–622. doi:10.​3275/​6379 PubMedCrossRef
27.
go back to reference Erdogan G, Erdogan MF, Delange F, Sav H, Gullu S, Kamel N (2000) Moderate to severe iodine deficiency in three endemic goitre areas from the Black Sea region and the capital of Turkey. Eur J Epidemiol 16(12):1131–1134PubMedCrossRef Erdogan G, Erdogan MF, Delange F, Sav H, Gullu S, Kamel N (2000) Moderate to severe iodine deficiency in three endemic goitre areas from the Black Sea region and the capital of Turkey. Eur J Epidemiol 16(12):1131–1134PubMedCrossRef
30.
go back to reference Dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, Dos Santos Faria M (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16(1):109–114. doi:10.1007/s11102-012-0383-y Dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, Montenegro R, Montenegro R Jr, Vilar L, Albano MF, Alves AR, Parente CV, Dos Santos Faria M (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16(1):109–114. doi:10.​1007/​s11102-012-0383-y
31.
go back to reference Clero E, Doyon F, Chungue V, Rachedi F, Boissin JL, Sebbag J, Shan L, Bost-Bezeaud F, Petitdidier P, Dewailly E, Rubino C, de Vathaire F (2012) Dietary iodine and thyroid cancer risk in French Polynesia: a case-control study. Thyroid 22(4):422–429. doi:10.1089/thy.2011.0173 PubMedCrossRef Clero E, Doyon F, Chungue V, Rachedi F, Boissin JL, Sebbag J, Shan L, Bost-Bezeaud F, Petitdidier P, Dewailly E, Rubino C, de Vathaire F (2012) Dietary iodine and thyroid cancer risk in French Polynesia: a case-control study. Thyroid 22(4):422–429. doi:10.​1089/​thy.​2011.​0173 PubMedCrossRef
32.
go back to reference Ozdemir D, Dagdelen S, Kiratli P, Tuncel M, Erbas B, Erbas T (2012) Changing clinical characteristics of thyroid carcinoma at a single center from Turkey: before and after the Chernobyl disaster. Minerva Endocrinol 37(3):267–274PubMed Ozdemir D, Dagdelen S, Kiratli P, Tuncel M, Erbas B, Erbas T (2012) Changing clinical characteristics of thyroid carcinoma at a single center from Turkey: before and after the Chernobyl disaster. Minerva Endocrinol 37(3):267–274PubMed
33.
go back to reference Tramontano D, Cushing GW, Moses AC, Ingbar SH (1986) Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology 119(2):940–942PubMedCrossRef Tramontano D, Cushing GW, Moses AC, Ingbar SH (1986) Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves’-IgG. Endocrinology 119(2):940–942PubMedCrossRef
34.
go back to reference Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, Giordano G (1989) Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab 68(3):621–626PubMedCrossRef Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, Giordano G (1989) Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab 68(3):621–626PubMedCrossRef
35.
go back to reference Onoda N, Ohmura E, Tsushima T, Ohba Y, Emoto N, Isozaki O, Sato Y, Shizume K, Demura H (1992) Autocrine role of insulin-like growth factor (IGF)-I in a human thyroid cancer cell line. Eur J Cancer 28A(11):1904–1909PubMedCrossRef Onoda N, Ohmura E, Tsushima T, Ohba Y, Emoto N, Isozaki O, Sato Y, Shizume K, Demura H (1992) Autocrine role of insulin-like growth factor (IGF)-I in a human thyroid cancer cell line. Eur J Cancer 28A(11):1904–1909PubMedCrossRef
37.
go back to reference Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European journal of endocrinology/European Federation of Endocrine Societies 151(4):439–446PubMedCrossRef Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European journal of endocrinology/European Federation of Endocrine Societies 151(4):439–446PubMedCrossRef
39.
go back to reference Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A(4):492–497PubMedCrossRef Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A(4):492–497PubMedCrossRef
40.
go back to reference Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396. doi:10.1016/S0140-6736(97)10384-1 PubMedCrossRef Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396. doi:10.​1016/​S0140-6736(97)10384-1 PubMedCrossRef
41.
go back to reference Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G (1998) Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 79(2):202–211PubMedCrossRef Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G (1998) Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 79(2):202–211PubMedCrossRef
42.
go back to reference Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47(3):209–217PubMedCrossRef Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47(3):209–217PubMedCrossRef
43.
go back to reference Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr (1991) Acromegaly and gastrointestinal cancer. Cancer 68(8):1673–1677PubMedCrossRef Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr (1991) Acromegaly and gastrointestinal cancer. Cancer 68(8):1673–1677PubMedCrossRef
44.
go back to reference Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Cosci C, Sardella C, Costa A, Gasperi M, Bartalena L, Martino E (2005) Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clin Endocrinol 63(6):683–688. doi:10.1111/j.1365-2265.2005.02405.x CrossRef Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Cosci C, Sardella C, Costa A, Gasperi M, Bartalena L, Martino E (2005) Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clin Endocrinol 63(6):683–688. doi:10.​1111/​j.​1365-2265.​2005.​02405.​x CrossRef
45.
go back to reference Dutta P, Bhansali A, Vaiphei K, Dutta U, Ravi Kumar P, Masoodi S, Mukherjee KK, Varma A, Kochhar R (2012) Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis? Pituitary 15(2):166–173. doi:10.1007/s11102-011-0300-9 PubMedCrossRef Dutta P, Bhansali A, Vaiphei K, Dutta U, Ravi Kumar P, Masoodi S, Mukherjee KK, Varma A, Kochhar R (2012) Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis? Pituitary 15(2):166–173. doi:10.​1007/​s11102-011-0300-9 PubMedCrossRef
46.
go back to reference Bustin SA, Dorudi S, Phillips SM, Feakins RM, Jenkins PJ (2002) Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol 23(3):130–138. doi:10.1159/000064029 PubMedCrossRef Bustin SA, Dorudi S, Phillips SM, Feakins RM, Jenkins PJ (2002) Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol 23(3):130–138. doi:10.​1159/​000064029 PubMedCrossRef
Metadata
Title
Increased thyroid cancer risk in acromegaly
Authors
Selcuk Dagdelen
Nese Cinar
Tomris Erbas
Publication date
01-08-2014
Publisher
Springer US
Published in
Pituitary / Issue 4/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0501-5

Other articles of this Issue 4/2014

Pituitary 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.